CSL Behring
A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 132
- Registration Number
- NCT05306275
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 81
- Registration Number
- NCT05130970
- Locations
- 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Pulmonary Associates Clinical Trials AZ, Phoenix, Arizona, United States
🇺🇸National Institute of Clinical Research, Huntington Beach, California, United States
Observatory of Patients With Haemophilia B Treated by IdElvion®
- Conditions
- Haemophilia B
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 222
- Registration Number
- NCT05086575
- Locations
- 🇫🇷
CHU Amiens - Picardie, Amiens, France
🇫🇷CH Annecy Genevois, Annecy, France
🇫🇷CHRU Besançon, Besançon, France
Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 171
- Registration Number
- NCT04739059
- Locations
- 🇺🇸
Clinical Research Center of Alabama, Birmingham, Alabama, United States
🇺🇸Research Solutions of Arizona, Litchfield Park, Arizona, United States
🇺🇸Medical Research of Arizona, Scottsdale, Arizona, United States
Register of Patients With haEmophilia A tReated With Afstyla®
- Conditions
- Haemophilia A
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 62
- Registration Number
- NCT04675541
- Locations
- 🇫🇷
CHU Brest, Brest, France
🇫🇷CHU Caen, Caen, France
🇫🇷CHU Chambéry, Chambéry, France
Hizentra® in Inflammatory Neuropathies - pHeNIx Study
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 100
- Registration Number
- NCT04672733
- Locations
- 🇫🇷
CHU Amiens Picardie 1, Amiens, France
🇫🇷CHU Angers, Angers, France
🇫🇷Hôpital privé de La Casamance, Aubagne, France
Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
- Conditions
- Von Willebrand Disease
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 135
- Registration Number
- NCT04657887
- Locations
- 🇫🇷
CHU Besançon, Besançon, France
🇫🇷CHU Bordeaux, Bordeaux, France
🇫🇷CHU Morvan Brest, Brest, France
CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks
- Conditions
- Hereditary Angioedema
- Interventions
- Biological: CSL312Drug: Placebo
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 64
- Registration Number
- NCT04656418
- Locations
- 🇺🇸
Clinical Research Center of Alabama, Birmingham, Alabama, United States
🇺🇸Medical Research of Arizona, Scottsdale, Arizona, United States
🇺🇸Raffi Tachdjian MD, Inc., Santa Monica, California, United States
Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)
- Conditions
- Noncystic Fibrosis Bronchiectasis (NCFB)
- Interventions
- Biological: CSL787Drug: Placebo
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 64
- Registration Number
- NCT04643587
- Locations
- 🇩🇪
IKF Pneumologie Institute, Frankfurt, Germany
🇬🇧Medicines Evaluation Unit (MEU), Manchester, England, United Kingdom
🇬🇧Celerion, Belfast, Northern Ireland, United Kingdom
Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- Biological: CSL760
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 12
- Registration Number
- NCT04638634
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, Australia